Literature DB >> 19710267

In vitro susceptibility of clinical isolates of Aspergillus spp. to anidulafungin, caspofungin, and micafungin: a head-to-head comparison using the CLSI M38-A2 broth microdilution method.

M A Pfaller1, L Boyken, R J Hollis, J Kroeger, S A Messer, S Tendolkar, D J Diekema.   

Abstract

We determined the in vitro activities of anidulafungin, caspofungin, and micafungin against 526 isolates of Aspergillus spp. (64 A. flavus, 391 A. fumigatus, 46 A. niger, and 25 A. terreus isolates) collected from over 60 centers worldwide from 2001 through 2007. Susceptibility testing was performed according to the CLSI M38-A2 method. All three echinocandins--anidulafungin (50% minimum effective concentration [MEC50], 0.007 microg/ml; MEC90, 0.015 microg/ml), caspofungin (MEC50, 0.015 microg/ml; MEC90, 0.03 microg/ml), and micafungin (MEC50, 0.007 microg/ml; MEC90, 0.015 microg/ml)-were very active against Aspergillus spp. More than 99% of all isolates were inhibited by < or = 0.06 microg/ml of all three agents.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19710267      PMCID: PMC2756949          DOI: 10.1128/JCM.01155-09

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  15 in total

1.  Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species.

Authors:  Frank C Odds; Mary Motyl; Roberto Andrade; Jacques Bille; Emilia Cantón; Manuel Cuenca-Estrella; Amanda Davidson; Christian Durussel; David Ellis; Elyse Foraker; Annette W Fothergill; Mahmoud A Ghannoum; Robert A Giacobbe; Miguel Gobernado; Rosemary Handke; Michel Laverdière; Wendy Lee-Yang; William G Merz; Luis Ostrosky-Zeichner; Javier Pemán; Sophia Perea; John R Perfect; Michael A Pfaller; Laurie Proia; John H Rex; Michael G Rinaldi; Juan-Luis Rodriguez-Tudela; Wiley A Schell; Christine Shields; Deanna A Sutton; Paul E Verweij; David W Warnock
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

2.  Caspofungin susceptibility in Aspergillus and non-Aspergillus molds: inhibition of glucan synthase and reduction of beta-D-1,3 glucan levels in culture.

Authors:  Jennifer Nielsen Kahn; Ming-Jo Hsu; Fred Racine; Robert Giacobbe; Mary Motyl
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

3.  A Ser678Pro substitution in Fks1p confers resistance to echinocandin drugs in Aspergillus fumigatus.

Authors:  Eleusa Maria F Rocha; Guillermo Garcia-Effron; Steven Park; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2007-08-27       Impact factor: 5.191

4.  Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.

Authors:  Thomas J Walsh; Elias J Anaissie; David W Denning; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; Brahm H Segal; William J Steinbach; David A Stevens; Jo-Anne van Burik; John R Wingard; Thomas F Patterson
Journal:  Clin Infect Dis       Date:  2008-02-01       Impact factor: 9.079

Review 5.  The echinocandins.

Authors:  Diane Cappelletty; Kasi Eiselstein-McKitrick
Journal:  Pharmacotherapy       Date:  2007-03       Impact factor: 4.705

6.  In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance.

Authors:  M A Pfaller; L Boyken; R J Hollis; J Kroeger; S A Messer; S Tendolkar; D J Diekema
Journal:  J Clin Microbiol       Date:  2007-11-21       Impact factor: 5.948

7.  Establishing in vitro-in vivo correlations for Aspergillus fumigatus: the challenge of azoles versus echinocandins.

Authors:  Maiken Cavling Arendrup; Susanne Perkhofer; Susan J Howard; Guillermo Garcia-Effron; Aimanianda Vishukumar; David Perlin; Cornelia Lass-Flörl
Journal:  Antimicrob Agents Chemother       Date:  2008-07-21       Impact factor: 5.191

8.  Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia.

Authors:  Charalampos Antachopoulos; Joseph Meletiadis; Tin Sein; Emmanuel Roilides; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2007-10-15       Impact factor: 5.191

9.  The role of echinocandins, extended-spectrum azoles, and polyenes to treat opportunistic moulds and Candida.

Authors:  Thomas F Patterson
Journal:  Curr Infect Dis Rep       Date:  2006-11       Impact factor: 3.663

10.  Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis.

Authors:  David W Denning; Kieren A Marr; Wendi M Lau; David P Facklam; Voravit Ratanatharathorn; Cornelia Becker; Andrew J Ullmann; Nita L Seibel; Patricia M Flynn; Jo-Anne H van Burik; Donald N Buell; Thomas F Patterson
Journal:  J Infect       Date:  2006-05-06       Impact factor: 6.072

View more
  35 in total

1.  Profiling the Aspergillus fumigatus proteome in response to caspofungin.

Authors:  Steven E Cagas; Mohit Raja Jain; Hong Li; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2010-10-25       Impact factor: 5.191

2.  Comparison of the broth microdilution methods of the European Committee on Antimicrobial Susceptibility Testing and the Clinical and Laboratory Standards Institute for testing itraconazole, posaconazole, and voriconazole against Aspergillus isolates.

Authors:  M Pfaller; L Boyken; R Hollis; J Kroeger; S Messer; S Tendolkar; D Diekema
Journal:  J Clin Microbiol       Date:  2011-01-05       Impact factor: 5.948

Review 3.  Echinocandins for the Treatment of Invasive Aspergillosis: from Laboratory to Bedside.

Authors:  Marion Aruanno; Emmanouil Glampedakis; Frédéric Lamoth
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

4.  Genetic Diversity and In Vitro Antifungal Susceptibility of 200 Clinical and Environmental Aspergillus flavus Isolates.

Authors:  Mojtaba Taghizadeh-Armaki; Mohammad Taghi Hedayati; Saham Ansari; Saeed Mahdavi Omran; Sasan Saber; Haleh Rafati; Jan Zoll; Henrich A van der Lee; Willem J G Melchers; Paul E Verweij; Seyedmojtaba Seyedmousavi
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

Review 5.  Echinocandin prophylaxis in patients undergoing haematopoietic cell transplantation and other treatments for haematological malignancies.

Authors:  David J Epstein; Susan K Seo; Janice M Brown; Genovefa A Papanicolaou
Journal:  J Antimicrob Chemother       Date:  2018-01-01       Impact factor: 5.790

6.  In vitro echinocandin susceptibility of Aspergillus isolates from patients enrolled in the Transplant-Associated Infection Surveillance Network.

Authors:  Shawn R Lockhart; Alicia J Zimbeck; John W Baddley; Kieren A Marr; David R Andes; Thomas J Walsh; Carol A Kauffman; Dimitrios P Kontoyiannis; James I Ito; Peter G Pappas; Tom Chiller
Journal:  Antimicrob Agents Chemother       Date:  2011-06-13       Impact factor: 5.191

7.  Polyphasic identification and susceptibility to seven antifungals of 102 Aspergillus isolates recovered from immunocompromised hosts in Greece.

Authors:  Michael Arabatzis; Manousos Kambouris; Miltiades Kyprianou; Aikaterini Chrysaki; Maria Foustoukou; Maria Kanellopoulou; Lydia Kondyli; Georgia Kouppari; Chrysa Koutsia-Karouzou; Evangelia Lebessi; Anastasia Pangalis; Efthimia Petinaki; Ageliki Stathi; Eleftheria Trikka-Graphakos; Erriketi Vartzioti; Aliki Vogiatzi; Timoleon-Achilleas Vyzantiadis; Loukia Zerva; Aristea Velegraki
Journal:  Antimicrob Agents Chemother       Date:  2011-03-28       Impact factor: 5.191

8.  Current role of echinocandins in the management of invasive aspergillosis.

Authors:  Małgorzata Mikulska; Claudio Viscoli
Journal:  Curr Infect Dis Rep       Date:  2011-12       Impact factor: 3.725

9.  Intrapulmonary pharmacokinetics and pharmacodynamics of micafungin in adult lung transplant patients.

Authors:  Thomas J Walsh; Sylvain Goutelle; Roger W Jelliffe; Jeffrey A Golden; Emily A Little; Catherine DeVoe; Diana Mickiene; Maggie Hayes; John E Conte
Journal:  Antimicrob Agents Chemother       Date:  2010-05-03       Impact factor: 5.191

10.  In vitro activity of a new oral glucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methods.

Authors:  Michael A Pfaller; Shawn A Messer; Mary R Motyl; Ronald N Jones; Mariana Castanheira
Journal:  Antimicrob Agents Chemother       Date:  2012-12-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.